247 related articles for article (PubMed ID: 36154176)
41. Real world outcomes of CFTR modulator therapy in Australian adults and children.
Kuek S; McCullagh A; Paul E; Armstrong D
Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
[TBL] [Abstract][Full Text] [Related]
42. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
43. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis.
Gramegna A; Contarini M; Aliberti S; Casciaro R; Blasi F; Castellani C
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824306
[TBL] [Abstract][Full Text] [Related]
44. Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor.
Gómez-Ganda L; Galván-Blasco P; Fernández-Polo A; Cardona V; García-Palop B; Parramón-Teixidó CJ; Polverino E; Álvarez-Fernández A
Front Pharmacol; 2024; 15():1392986. PubMed ID: 38933680
[No Abstract] [Full Text] [Related]
45. Radiological and long-term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease.
Aalbers BL; Mohamed Hoesein FAA; Hofland RW; Bronsveld I; Kruijswijk MA; Schotman S; Slingerland CW; Panhuis H; van der Ent CK; Heijerman HGM
Pediatr Pulmonol; 2023 Aug; 58(8):2317-2322. PubMed ID: 37222401
[TBL] [Abstract][Full Text] [Related]
46. Challenged Urine Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane Conductance Regulator Function in Cystic Fibrosis.
Berg P; Sorensen MV; Rousing AQ; Vebert Olesen H; Jensen-Fangel S; Jeppesen M; Leipziger J
Ann Intern Med; 2022 Nov; 175(11):1543-1551. PubMed ID: 36315944
[TBL] [Abstract][Full Text] [Related]
47. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
48. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.
Fajac I; Daines C; Durieu I; Goralski JL; Heijerman H; Knoop C; Majoor C; Bruinsma BG; Moskowitz S; Prieto-Centurion V; Van Brunt K; Zhang Y; Quittner A
J Cyst Fibros; 2023 Jan; 22(1):119-123. PubMed ID: 36114142
[TBL] [Abstract][Full Text] [Related]
49. CFTR Modulators: Current Status and Evolving Knowledge.
Regard L; Martin C; Da Silva J; Burgel PR
Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.
Kapouni N; Moustaki M; Douros K; Loukou I
Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980112
[TBL] [Abstract][Full Text] [Related]
51. Measuring the effect of elexacaftor/tezacaftor/ivacaftor combination therapy on the respiratory pump in people with CF using dynamic chest radiography.
FitzMaurice TS; McCann C; Nazareth D; Shaw M; McNamara PS; Walshaw MJ
J Cyst Fibros; 2022 Nov; 21(6):1036-1041. PubMed ID: 35101365
[TBL] [Abstract][Full Text] [Related]
52. Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.
Stapleton AL; Kimple AJ; Goralski JL; Nouraie SM; Branstetter BF; Shaffer AD; Pilewski JM; Senior BA; Lee SE; Zemke AC
J Cyst Fibros; 2022 Sep; 21(5):792-799. PubMed ID: 35300931
[TBL] [Abstract][Full Text] [Related]
53. Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation.
Roder L; Simonsen M; Fitzpatrick L; He J; Loucks J
J Manag Care Spec Pharm; 2022 Sep; 28(9):989-996. PubMed ID: 36001103
[No Abstract] [Full Text] [Related]
54. Improvements in Glucose Regulation in Children and Young People with Cystic Fibrosis-Related Diabetes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor.
Park J; Walsh A; Kerr S; Woodland C; Southward S; Deakin M; Senniappan S; Thursfield R
Horm Res Paediatr; 2024; 97(1):94-98. PubMed ID: 37040724
[TBL] [Abstract][Full Text] [Related]
55. Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial.
Flume PA; Harris RS; Paz-Diaz H; Ahluwalia N; Higgins M; Campbell D; Berhane I; Shih JL; Sawicki G
J Cyst Fibros; 2023 May; 22(3):464-470. PubMed ID: 36581484
[TBL] [Abstract][Full Text] [Related]
56. Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study.
Korten I; Kieninger E; Krueger L; Bullo M; Flück CE; Latzin P; Casaulta C; Boettcher C
Front Pediatr; 2022; 10():852551. PubMed ID: 35529332
[TBL] [Abstract][Full Text] [Related]
57. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
Hoy SM
Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
[TBL] [Abstract][Full Text] [Related]
58. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.
Rysgaard UK; Pedersen CL; Jensen JH; Sørensen L; Philipsen LKD; Leo-Hansen C; Olesen HV
J Cyst Fibros; 2022 Sep; 21(5):844-849. PubMed ID: 35667973
[TBL] [Abstract][Full Text] [Related]
59. A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation.
Knott-Torcal C; Sebastián-Valles F; Girón Moreno RM; Martín-Adán JC; Jiménez-Díaz J; Marazuela M; Sánchez de la Blanca N; Fernández-Contreras R; Arranz-Martín A
Clin Nutr; 2023 Dec; 42(12):2468-2474. PubMed ID: 38411018
[TBL] [Abstract][Full Text] [Related]
60. Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash.
Santos AI; Pacheco J; Cemlyn-Jones J; Gamboa F
Cureus; 2023 Sep; 15(9):e46228. PubMed ID: 37905296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
